Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human, Dose Finding, Open Label Phase 1A-1B Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

NCT03199586 is registered in ClinicalTrials.gov with Novita Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03199586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03199586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human, Dose Finding, Open Label Phase 1A-1B Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Lead sponsor
Novita Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 21, 2017
Completion date
May 7, 2020
Enrollment
23 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic treatment-refractory solid tumor malignancies, breast cancer, colon cancer, esophagus cancer, liver cancer, lung cancer, ovary cancer, pancreas cancer, prostate cancer